Autopsy report · NCT00903630
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Cause of deathFunding or business
“lack of funding”
Life of this trial
- Ran for about 2 years 4 months before it stopped.
- 15 participants enrolled.
- Results were posted on the registry 5 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Sponsor type
- University, hospital or other
- Conditions
- Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
- Interventions
- Lenalidomide; liposomal doxorubicin
- Participants
- 15
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.